Biohaven Pharmaceutical Holding Company Ltd. Aktie News
11,53 $
0,79 %
NYSE,
12. Dezember, 22:00 Uhr
tracken
Biohaven Pharmaceutical Holding Company Ltd. Aktie News
Neutral
PRNewsWire
●
4 Tage alt
In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective response rates 3/5 (60%) in NSCLC, 4/4 (100%) in endometrial cancer, and 1/2 (50%) in urothelial cancer There were low rates of adverse events attributed to unconjugated payload such as hematological tox...
Positiv
MarketBeat
●
25 Tage alt
When corporate executives make multi-million-dollar personal investments in the company they lead, it is one of the most potent signals an investor can receive. At Biohaven NYSE: BHVN, that signal has just been sent loud and clear.
Neutral
The Motley Fool
●
25 Tage alt
On November 17, 2025, Biohaven's Chief Accounting Officer, George Clark, acquired 17,000 shares of company stock. Mr. Clark's purchase was valued at approximately $144,800.
Neutral
PRNewsWire
●
etwa ein Monat alt
NEW HAVEN, Conn. , Nov. 13, 2025 /PRNewswire/ -- Biohaven Ltd.
Positiv
Seeking Alpha
●
etwa ein Monat alt
Biohaven (BHVN) narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending and steep share price declines. BHVN's pipeline includes Opakalim for depression and epilepsy, TRAP/MoDE degraders for IgA nephropathy and Graves' disease, and Taldefgrobep alfa for obesity and spinal muscular atrophy. Despite intriguing science and large market opportun...
Neutral
PRNewsWire
●
etwa ein Monat alt
NEW HAVEN, Conn. , Nov. 12, 2025 /PRNewswire/ -- Biohaven Ltd.
Neutral
PRNewsWire
●
etwa ein Monat alt
NEW HAVEN, Conn. , Nov. 11, 2025 /PRNewswire/ -- Biohaven Ltd.
Neutral
PRNewsWire
●
etwa ein Monat alt
NEW HAVEN, Conn. , Nov. 10, 2025 /PRNewswire/ -- Biohaven Ltd.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
